BLGO vs. ASPI, LXFR, LNZA, ARQ, SLI, ORGN, TSE, AMTX, SDST, and ALTO
Should you be buying BioLargo stock or one of its competitors? The main competitors of BioLargo include ASP Isotopes (ASPI), Luxfer (LXFR), LanzaTech Global (LNZA), ARQ (ARQ), Standard Lithium (SLI), Origin Materials (ORGN), Trinseo (TSE), Aemetis (AMTX), Stardust Power (SDST), and Alto Ingredients (ALTO). These companies are all part of the "chemicals" industry.
BioLargo vs.
ASP Isotopes (NASDAQ:ASPI) and BioLargo (NASDAQ:BLGO) are both small-cap basic materials companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.
ASP Isotopes currently has a consensus price target of $4.50, suggesting a potential downside of 29.69%. Given ASP Isotopes' stronger consensus rating and higher possible upside, research analysts clearly believe ASP Isotopes is more favorable than BioLargo.
16.8% of ASP Isotopes shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 21.4% of ASP Isotopes shares are held by insiders. Comparatively, 20.3% of BioLargo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
BioLargo received 104 more outperform votes than ASP Isotopes when rated by MarketBeat users. However, 100.00% of users gave ASP Isotopes an outperform vote while only 60.99% of users gave BioLargo an outperform vote.
In the previous week, ASP Isotopes had 28 more articles in the media than BioLargo. MarketBeat recorded 32 mentions for ASP Isotopes and 4 mentions for BioLargo. BioLargo's average media sentiment score of 0.22 beat ASP Isotopes' score of 0.10 indicating that BioLargo is being referred to more favorably in the news media.
BioLargo has a net margin of -11.45% compared to ASP Isotopes' net margin of -807.39%. BioLargo's return on equity of -39.90% beat ASP Isotopes' return on equity.
ASP Isotopes has a beta of 3.48, indicating that its share price is 248% more volatile than the S&P 500. Comparatively, BioLargo has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.
BioLargo has higher revenue and earnings than ASP Isotopes. BioLargo is trading at a lower price-to-earnings ratio than ASP Isotopes, indicating that it is currently the more affordable of the two stocks.
Summary
ASP Isotopes beats BioLargo on 10 of the 18 factors compared between the two stocks.
Get BioLargo News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLGO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLargo Competitors List
Related Companies and Tools
This page (NASDAQ:BLGO) was last updated on 1/21/2025 by MarketBeat.com Staff
